Showing results (271-280 of 323) with videos related to
Sort By:
Pageof 33
Annals of Neurology|December 29, 2017
Homozygous boricua TBCK mutation causes neurodegeneration and aberrant autophagyXilma R Ortiz-González, Jesus A Tintos-Hernández, Kierstin Keller, et al.Pediatric Research|March 7, 2003
Molecular analysis of the GNAS1 gene for the correct diagnosis of Albright hereditary osteodystrophy and pseudohypoparathyroidismLuisa De Sanctis, Damiano Romagnolo, Martina Olivero, et al.Journal of Pediatric Urology|December 2, 2014
Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system)Hiep T Nguyen, Carol B Benson, Bryann Bromley, et al.Brain Pathology (Zurich, Switzerland)|November 17, 2009
Gene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factorsKarin Boer, Peter B Crino, Jan A Gorter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trialFederico Cappuzzo, Claudia Ligorio, Pasi A Jänne, et al.Cerebral Cortex (New York, N.Y. : 1991)|October 20, 2012
Fetal brain mTOR signaling activation in tuberous sclerosis complexVictoria Tsai, Whitney E Parker, Ksenia A Orlova, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2007
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinibF R Hirsch, M Varella-Garcia, F Cappuzzo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancerSuresh S Ramalingam, David R Spigel, David Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerPasi A Jänne, Joachim von Pawel, Roger B Cohen, et al.Brain : a Journal of Neurology|May 25, 2007
Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5Erik G Puffenberger, Kevin A Strauss, Keri E Ramsey, et al.Pageof 33